BEST VENTURE INVESTMENT EXPERTISE IN PHARMACEUTICALS AND LIFE SCIENCES
Creating world-class Russian-domiciled expertise in the field of venture capital financing in the medical, pharmaceutical and biotechnology sectors;
UNIQUE PORTFOLIO OF INNOVATIONS
Localization in Russia of the world’s most promising and advanced innovative medicines and associated technologies through acquisition/in-licensing of the intellectual property rights for Russia of the companies in which RusnanoMedInvest takes an investment stake
CONTRIBUTION TO THE DEVELOPMENT OF THE RUSSIAN PHARMACEUTICALS AND LIFE SCIENCES INDUSTRIES
Significant contribution to the modernization of the Russian pharmaceutical industry and its integration with international leaders in medicine and pharmaceuticals, including the largest investment funds, pharmaceutical companies and research centers in order to proactively facilitate the integration of the emerging Russian life sciences innovation clusters into theglobal innovation value chains in life sciences and associated industries
SIGNIFICANT BENEFITS FOR RUSSIAN SOCIETY OVERALL
The fund has set itself a clear objective of generating increased interest from the Russian investment community in venture capital investments in both Russian and international companies and other new ventures in the field of Life Sciences.
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
26 April 2017
25 April 2017